Serum Institute of India is conducting Phase 3 trials of a BCG vaccine to evaluate its ability in reducing COVID-19 infection and severe disease outcomes among high-risk persons, Department of Biotechnology said. Around 6,000 individuals have been enrolled for trial. BCG vaccine is administered routinely to newborns as part of the national childhood immunisation programme to prevent tuberculosis.